On Thursday, BofA Securities analyst Travis Steed reduced the price target on Embecta shares (NASDAQ: EMBC) to $18.00, down from the previous $20.00, while maintaining an Underperform rating on the ...

To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Embecta began a restructuring plan in its fiscal second quarter, the company announced on Friday ...

Embecta Corp, a medical device company with a market capitalization of $773 million, reported its second-quarter fiscal year 2025 results, surpassing earnings expectations with an EPS of $0.70 ...

Embecta sees FY 2025 revenue of $1.07B-$1.09B versus the analyst consensus of $1.09B. Embecta’s stock price closed at $13.30. It is down -23.65% in the last 3 months and down -6.60% in the last 12 ...

Embecta Corp (NASDAQ: EMBC) reported its second-quarter fiscal year 2025 results on May 9, 2025, revealing a revenue decline offset by margin improvements and continued debt reduction. The diabetes ...

NEW YORK - Embecta Corp. (NASDAQ:EMBC) reported better-than-expected second quarter results on Friday, as the diabetes care company beat analyst estimates for both earnings and revenue.

PARSIPPANY, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three and six ...

PARSIPPANY, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will hold an Analyst and ...

Please provide your email address to receive an email when new articles are posted on . A group of experts updated the FITTER insulin injection recommendations for the first time since 2016. The ...

PARSIPPANY, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its ...